BACKGROUND - Incontinence has a greater detrimental effect on quality of life than other symptoms of overactive bladder (OAB) and is often difficult to treat with antimuscarinic monotherapy.
OBJECTIVE - To evaluate the efficacy and the safety and tolerability of combination (solifenacin 5mg and mirabegron 50mg) versus solifenacin 5 or 10mg in OAB patients remaining incontinent after 4 wk of solifenacin 5mg.
DESIGN, SETTING, AND PARTICIPANTS - OAB patients remaining incontinent despite daily solifenacin 5mg during 4-wk single-blind run-in were randomised 1:1:1 to double-blind daily combination or solifenacin 5 or 10mg for 12 wk. Patients receiving the combination were initiated on mirabegron 25mg increasing to 50mg after week 4.
OUTCOME MEASURES AND STATISTICAL ANALYSIS - The primary end point was a change from baseline to end of treatment (EOT) in the mean number of incontinence episodes per 24h (stratified rank analysis of covariance [ANCOVA]). Key secondary end points were a change from baseline to EOT in the mean number of micturitions per 24h (ANCOVA) and number of incontinence episodes noted in a 3-d diary at EOT (mixed-effects Poisson regression). A trial (BESIDE) comparing combination treatment (solifenacin plus mirabegron) with one treatment alone (solifenacin) tested the superiority of combination versus solifenacin 5mg, noninferiority (and potential superiority) of combination versus solifenacin 10mg (key secondary end points), and the safety and tolerability of combination therapy versus solifenacin monotherapy.
RESULTS AND LIMITATIONS - A total of 2174 patients were randomised to combination (n=727), solifenacin 5mg (n=728), or solifenacin 10mg (n=719). At EOT, combination was superior to solifenacin 5mg, with significant improvements in daily incontinence (p=0.001), daily micturitions (p<0.001), and incontinence noted in a 3-d diary (p=0.014). Combination was noninferior to solifenacin 10mg for key secondary end points and superior to solifenacin 10mg for improving daily micturitions. All treatments were well tolerated.
CONCLUSIONS - Adding mirabegron 50mg to solifenacin 5mg further improved OAB symptoms versus solifenacin 5 or 10mg, and it was well tolerated in OAB patients remaining incontinent after initial solifenacin 5mg.
PATIENT SUMMARY - In this 12-wk study, overactive bladder patients who remained incontinent despite initial solifenacin 5mg treatment received additional treatment with mirabegron 50mg. Combining mirabegron 50mg with solifenacin 5mg was superior to solifenacin 5mg alone in improving symptoms of incontinence and frequent urination, and it was well tolerated.
TRIAL REGISTRATION - ClinicalTrials.gov NCT01908829.
European urology. 2016 Mar 07 [Epub ahead of print]
Marcus J Drake, Christopher Chapple, Ahmet A Esen, Stavros Athanasiou, Javier Cambronero, David Mitcheson, Sender Herschorn, Tahir Saleem, Moses Huang, Emad Siddiqui, Matthias Stölzel, Claire Herholdt, Scott MacDiarmid, BESIDE study investigators
University of Bristol and Bristol Urological Institute, Bristol, UK. Royal Hallamshire Hospital and Sheffield Hallam University, Sheffield, UK., Dokuz Eylül University School of Medicine, İzmir, Turkey., University of Athens Medical School, Athens, Greece., Infanta Leonor Hospital, Madrid, Spain., St. Elizabeth's Medical Center, Brighton, MA, USA., Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Astellas Pharma Europe Ltd, Chertsey, Surrey, UK., Astellas Pharma Europe Ltd, Chertsey, Surrey, UK., Astellas Pharma Europe Ltd, Chertsey, Surrey, UK., Astellas Pharma Global Development, Leiden, The Netherlands., Astellas Pharma Europe Ltd, Chertsey, Surrey, UK., Alliance Urology Specialists, Greensboro, NC, USA.